05-Jan-2021 - ViGeneron GmbH

ViGeneron and Biogen collaborate

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

ViGeneron GmbH announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections.

“Gene therapy has become a clinical reality. At ViGeneron, we are dedicated to developing innovative gene therapies to treat diseases with high unmet medical need. This collaboration exemplifies our strategy to develop in-house programs for selected retinal targets, while maximizing our proprietary technology platforms with additional collaboration programs for other targets in ophthalmology and further indications,” said Dr. Caroline Man Xu, Co-founder and CEO of ViGeneron. “ViGeneron’s recognized expertise in retinal gene therapy together with Biogen’s leading research, drug development and commercialization experience is a powerful combination that we believe will allow us to deliver more novel gene therapies to patients in need.”

Within the collaboration, ViGeneron will optimize and validate in vitro therapeutic candidates for an undisclosed target to treat inherited eye disease. Biogen has the right to add an additional reserved target within two years after the effective date. The companies will work together on the in vivo proof of concept (POC). Biogen will be responsible for all further development and commercialization of the selected therapeutic candidates.

ViGeneron will receive from Biogen an upfront payment and R&D funding for the mutually agreed workplan. In addition, ViGeneron will be eligible to receive development, regulatory and commercial milestone payments, and will also be eligible to receive tiered royalties on net commercial sales of products arising from the collaboration.

Facts, background information, dossiers
More about ViGeneron
  • News

    Start-up ViGeneron announces research collaboration with Daiichi Sankyo

    ViGeneron GmbH, a gene therapy company, announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited, for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmi ... more

    ViGeneron closes of series A financing to drive development of next generation gene therapy pipeline

    ViGeneron GmbH announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China. The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy ... more

  • Companies

    ViGeneron GmbH

    ViGeneron is a next generation gene therapy company dedicated to develop the innovative medicines of the future. Our team seeks to solve the major limitations of current gene therapy approaches. ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich. more

More about Biogen
  • News

    Siemens and Biogen cooperate

    Siemens Healthineers and Biogen announced that the companies plan to jointly develop magnetic resonance imaging (MRI) applications with the intent of quantifying key markers of multiple sclerosis (MS) disease activity and progression. Siemens Healthineers aims to enable healthcare providers ... more

    Antibody reduces harmful brain amyloid plaques in Alzheimer's patients

    Aducanumab, an antibody developed by the University of Zurich, has been shown to trigger a meaningful reduction of harmful beta-amyloid plaques in patients with early-stage Alzheimer's disease. These protein deposits in the brain are a classic sign of Alzheimer's disease and contribute to t ... more

    Biogen names executive vice president

    Biogen announced the appointment of Paul McKenzie, Ph.D., as executive vice president, Pharmaceutical Operations & Technology, effective July 1, 2016. He will report to George A. Scangos, Ph.D., chief executive officer, and will be a member of the Biogen management team. Dr. McKenzie was pr ... more

  • Companies

    Biogen Spain, S.L.

    Our commitment to research in Multiple Sclerosis is further strengthened through the Biogen Foundation, dedicated to the promotion of training, dissemination, research and scientific development and health promotion, as well as the development of other activities that contribute To improve ... more

    Biogen Austria Ges.m.b.H.

    more